Constellation Kidney Group Marks 50 Years of Dialysis Innovation, Introducing KidneyOne to Power the Next Generation of Kidney Care
RICHMOND, Va. — Constellation Kidney Group (CKG), a global portfolio of businesses under Miram Solutions within the Perseus Operating Group (Perseus) of Constellation Software Inc. (TSX: CSU), proudly commemorates 50 years of dialysis technology innovation, honoring the legacy of Quantitative Medical Systems Inc. (QMS), founded in Oakland, California in 1976. Acquired by Perseus in 2013, QMS laid the foundation for what is now a global leader in integrated clinical, operational, and analytics solutions for kidney care providers.
Article content
To mark this milestone, CKG is unveiling a refreshed brand identity and introducing its next-generation product ecosystem:
Article content
Article content
KidneyOne, a fully integrated dialysis management platform;
CKG Intelligence, a powerful analytics suite, including the Renal AI predictive care solution; and
CKG Exchange, a robust interoperability hub for the future, connecting data across the kidney care continuum.
Article content
'Celebrating 50 years is a testament to the incredible legacy of QMS and the ongoing commitment of Constellation Kidney Group to empower dialysis providers with technology that makes a meaningful difference,' said David Abbott, General Manager of CKG. 'As part of the Constellation Software family, our ethos has always been to acquire and nurture vertical market software businesses for the long term, ensuring continuous innovation and lasting value for our customers.'
Article content
CKG's KidneyOne platform brings together its market-leading solutions into a single, unified ecosystem — enhancing workflows, delivering actionable insights, and helping dialysis providers optimize care, operations, and compliance across global markets.
Article content
'KidneyOne gives providers a smarter, more connected way to run their dialysis operations while supporting better outcomes and reducing costs,' said Chris Lutz, General Manager, CKG US. 'By uniting best-in-class solutions with AI-driven analytics and integrated workflows in a single platform, we're defining the next generation of dialysis software built to scale for long-term growth.'
Article content
The 50th anniversary milestone reflects CKG's enduring mission to advance kidney care through purpose-built technology, reliability, and long-term partnership. Visit the company's updated website to learn more: www.constellationkidney.com About Constellation Kidney Group Constellation Kidney Group (CKG) is a global leader in dialysis technology, delivering purpose-built clinical, financial, and operational solutions that empower kidney care providers worldwide. Formed through the acquisition of leading software innovators beginning in 2013, CKG brings together decades of expertise in KidneyOne — an integrated platform offering modern EHR applications, data-driven intelligence, and seamless interoperability through CKG Exchange. CKG is a global portfolio of businesses under Miram Solutions within the Perseus Operating Group of Constellation Software Inc. (TSX: CSU), and is committed to advancing kidney care through innovation, reliability, and long-term partnership. Learn more at www.constellationkidney.com
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a minute ago
- Globe and Mail
US Bancorp Reports Strong Q2 2025 Financial Results
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. US Bancorp ( (USB)) has shared an announcement. US Bancorp reported strong financial results for the second quarter of 2025, with a net income of $1,815 million, marking a 13.2% increase year-over-year. The company achieved a return on tangible common equity of 18% and a return on average assets of 1.08%. The results were driven by growth in fee revenue, particularly in payment services, trust and investment management, and treasury management fees. Elavon, a subsidiary of US Bancorp, improved its ranking in the 2025 Nilson Report, becoming the fifth-largest U.S. merchant acquirer. Additionally, US Bancorp completed its first fully digital trade finance transaction, highlighting its commitment to modernizing trade and working capital for clients. The most recent analyst rating on (USB) stock is a Hold with a $49.00 price target. To see the full list of analyst forecasts on US Bancorp stock, see the USB Stock Forecast page. Spark's Take on USB Stock According to Spark, TipRanks' AI Analyst, USB is a Outperform. US Bancorp presents a well-rounded investment case with strong technical momentum and attractive valuation. Robust earnings call guidance and positive corporate events further bolster confidence. However, the financial performance could be improved with enhanced revenue growth and equity strength. To see Spark's full report on USB stock, click here. US Bancorp operates in the financial services industry, providing a range of banking and financial products including payment services, trust and investment management, and treasury management. The company focuses on leveraging its diversified business mix and sound risk management to navigate economic volatility. Average Trading Volume: 9,768,842 Technical Sentiment Signal: Strong Buy Current Market Cap: $71.19B See more insights into USB stock on TipRanks' Stock Analysis page.
Globe and Mail
a minute ago
- Globe and Mail
The triple contradiction of Trumponomics could crash the world economy
Donald Trump wants three things from the U.S. economy. First, the U.S. President wants lower interest rates. It infuriates him that his country's baseline rate lingers at 4.5 per cent, which makes it very expensive to service the trillions in national debt his tax cuts have rung up. Washington will need to pay an estimated US$665-billion, more than all its defence spending, on interest payments this year. Mr. Trump recently posted a list of countries that have lower interest rates, including Canada, with a handwritten note telling Federal Reserve Chair Jerome Powell that rates should be more like those of recession-threatened countries such as Japan or Thailand. This week he went as far as writing (but not sending) a letter firing Mr. Powell, who he called 'a knucklehead' and a 'stupid guy.' Second, he wants manufacturing to move back to the United States. This is the most plausible of the many, largely fictitious, reasons he's given for his punitive tariffs. U.S. companies, he says, should escape his tariff threat by shutting down branch plants and 'reshoring' manufacturing, especially of labour-intensive products such as smartphones and cars. Third, Mr. Trump wants fewer working-age people in the United States. Not only has he reduced most forms of immigration to near zero, he is attempting a mass deportation campaign that would throw hundreds of thousands of people, most currently employed, out of the U.S. If he succeeds – and Congress has recently given him the funds to do it – then projections show the U.S. working-age population could decline by 3.3 million workers by the end of this year, and by 8 million by 2030. Opinion: Trump has already crossed Fed independence Rubicon Mr. Trump seems unaware that these three policy goals all contradict one another. If he fully achieves any one of them, the other two will become impossible. If he genuinely attempts any two, we will all be hurt by the resulting worldwide economic catastrophe. The reason why some countries have lower interest rates than the United States is no mystery: Those countries aren't experiencing much economic growth, and need looser money to stimulate it. In most cases, including Canada's, they have higher levels of unemployment, so an upturn in growth would result in increased employment rather than a wage-driven inflation shock. The United States is in a different position. This week – a day before Mr. Trump threatened the central bank chief – Americans learned their inflation rate had risen to a disquieting 2.7 per cent, largely due to Mr. Trump's tariffs driving up prices of goods. Given that his more dramatic tariffs, such as his threatened 35-per-cent rate against Canada, have yet to take effect, any rate cut at this point would likely trigger a reprise of the pandemic-recovery inflation spike of 2022-2023 – an event whose lingering mood of anxiety contributed significantly to Mr. Trump's election victory. The problem Mr. Trump faces is not just that the economy is dangerously close to overheating and spiraling into serious inflation, it's that this is in large part due to the extremely tight U.S. labour market. Unemployment in the United States is currently 4.1 per cent – far below the approximately 5-per-cent rate that economists consider 'full employment.' In other words, his country appears to be short several million workers, at the exact moment its President is planning to expel or exclude millions more workers. Opinion: Trump's trade war madness won't last That makes inflation much more likely, and higher interest rates more necessary. But it also makes it near-impossible to 'reshore' major industries to the United States. Unlike the successful reshoring initiatives under the Obama and Biden administrations – which were driven by policies and incentives – Mr. Trump hopes manufacturers will simply come back to escape the tariffs. But moving, say, a major car factory from Ontario to Wisconsin would also require hundreds of parts companies to be located close to the plant, thus shifting tens or hundreds of thousands of jobs into a state that's already short of workers. Even outspoken advocates of reshoring say Mr. Trump's immigration crackdown, amidst already more-than-full employment, makes such moves impossible. 'If he achieves his objective, which is our objective, to let's say increase manufacturing by 40 per cent – that's 5 million workers,' Harry Moser, head of the Florida-based Reshoring Initiative, recently told Wisconsin Public Radio. 'If you don't have the work force, it's not going to happen. There's going to be nobody to man the factories.' Mr. Trump's deportations and tariffs are driving up inflation and making reshoring more difficult. They're also forcing interest rates to stay high. Cutting rates or reshoring major employers without immigration would provoke unprecedented levels of inflation and likely supply failures. It's the triple contradiction of Trumponomics: Pull hard on any one of his threads, and the whole tent crashes down.
National Post
a minute ago
- National Post
Trump has chronic venous insufficiency. Here's what the White House doctor said about the diagnosis
Donald Trump, 79, has been diagnosed with chronic venous insufficiency after he was examined for swelling in his lower legs, White House press secretary Karoline Leavitt said Thursday. Although the swelling was 'mild,' the condition caused blood to pool in the U.S. president's legs. Article content Leavitt addressed Trump's condition at a press conference briefly, calling it 'benign' and common in people over the age of 70. She added that there is no evidence of Trump's condition being serious or life-threatening, as revealed by further and 'compressive' tests. Article content Article content JUST IN: President Trump underwent vascular testing after he had swelling in his legs. "All results were within normal limits ... and the president remains in excellent health," White House press secretary Karoline Leavitt said. — ABC News (@ABC) July 17, 2025 Article content Here's what we know about Trump's condition, how it is treated and what the letter from Trump's doctor says. Article content Blood is normally pumped all over the body. Veins in the body then take the blood insufficient in oxygen back to the heart to refuel. In some cases, veins aren't able to carry out that function properly and as a result the blood pools in the legs. This condition is known as chronic venous insufficiency. Article content Cleveland Clinic notes that 'this increases pressure in the leg veins and causes symptoms like swelling and ulcers.' The academic centre encourages lifestyle changes as the first method of treatment for this condition. Article content Article content 'If these measures aren't enough, your provider may recommend a procedure or surgery. 'The best treatment for you depends on how far your condition has progressed and other medical conditions you have,' according to Cleveland Clinic. Article content What did the White House physician's letter say? Article content The letter by Trump's doctor explained that the diagnosis came after Trump underwent a comprehensive examination as the president noted mild swelling his legs. Results for other tests 'were within normal limits,' physician Capt. Sean Barbabella wrote. 'No signs of heart failure, renal impairment, or systemic illness were identified,' the letter continued. Article content Article content Article content Article content 'This is consistent with minor soft tissue irritation from frequent handshaking and the use of aspirin, which is taken as part of a standard cardiovascular prevention regimen,' Barbabella wrote. 'This is a well-known and benign side effect of aspirin therapy.' Article content
